<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32494709</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>19</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates.</ArticleTitle><Pagination><StartPage>eaaz2433</StartPage><MedlinePgn>eaaz2433</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eaaz2433</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.aaz2433</ELocationID><Abstract><AbstractText>Coxsackievirus B (CVB) enteroviruses are common human pathogens known to cause severe diseases including myocarditis, chronic dilated cardiomyopathy, and aseptic meningitis. CVBs are also hypothesized to be a causal factor in type 1 diabetes. Vaccines against CVBs are not currently available, and here we describe the generation and preclinical testing of a novel hexavalent vaccine targeting the six known CVB serotypes. We show that the vaccine has an excellent safety profile in murine models and nonhuman primates and that it induces strong neutralizing antibody responses to the six serotypes in both species without an adjuvant. We also demonstrate that the vaccine provides immunity against acute CVB infections in mice, including CVB infections known to cause virus-induced myocarditis. In addition, it blocks CVB-induced diabetes in a genetically permissive mouse model. Our preclinical proof-of-concept studies demonstrate the successful generation of a promising hexavalent CVB vaccine with high immunogenicity capable of preventing CVB-induced diseases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>V M</ForeName><Initials>VM</Initials><Identifier Source="ORCID">0000-0003-3091-2142</Identifier><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hankaniemi</LastName><ForeName>M M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0001-6463-1248</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laitinen</LastName><ForeName>O H</ForeName><Initials>OH</Initials><Identifier Source="ORCID">0000-0002-3751-9952</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sioofy-Khojine</LastName><ForeName>A B</ForeName><Initials>AB</Initials><Identifier Source="ORCID">0000-0001-5538-5153</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>A</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5662-1576</Identifier><AffiliationInfo><Affiliation>Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz Lozano</LastName><ForeName>I M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazur</LastName><ForeName>M A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marjom&#xe4;ki</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Biological and Environmental Science/Nanoscience Center, University of Jyv&#xe4;skyl&#xe4;, Jyv&#xe4;skyl&#xe4;, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lor&#xe9;</LastName><ForeName>K</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-7679-9494</Identifier><AffiliationInfo><Affiliation>Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hy&#xf6;ty</LastName><ForeName>H</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-0370-4145</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fimlab Laboratories, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyt&#xf6;nen</LastName><ForeName>V P</ForeName><Initials>VP</Initials><Identifier Source="ORCID">0000-0002-9357-1480</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fimlab Laboratories, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flodstr&#xf6;m-Tullberg</LastName><ForeName>M</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2685-2052</Identifier><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="Y">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="Y">Myocarditis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011323" MajorTopicYN="N">Primates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017778" MajorTopicYN="N">Vaccines, Combined</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>5</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32494709</ArticleId><ArticleId IdType="pmc">PMC7202868</ArticleId><ArticleId IdType="doi">10.1126/sciadv.aaz2433</ArticleId><ArticleId IdType="pii">aaz2433</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abedi G. R., Watson J. T., Nix W. A., Oberste M. S., Gerber S. I., Enterovirus and parechovirus surveillance&#x2014;United States, 2014&#x2013;2016. MMWR Morb. Mortal. Wkly. Rep. 67, 515&#x2013;518 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5944979</ArticleId><ArticleId IdType="pubmed">29746455</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavakoli N. P., Wang H., Nattanmai S., Dupuis M., Fusco H., Hull R., Detection and typing of enteroviruses from CSF specimens from patients diagnosed with meningitis/encephalitis. J. Clin. Virol. 43, 207&#x2013;211 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18692435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong J., Kang B., Yeo S., Jee Y., Park J.-H., Pathogenesis of coxsackievirus B2 in mice: Characterization of clinical isolates of the coxsackievirus B2 from patients with myocarditis and aseptic meningitis in Korea. J. Vet. Sci. 18, 457&#x2013;464 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5746438</ArticleId><ArticleId IdType="pubmed">28384999</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairweather D., Stafford K. A., Sung Y. K., Update on coxsackievirus B3 myocarditis. Curr. Opin. Rheumatol. 24, 401&#x2013;407 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4536812</ArticleId><ArticleId IdType="pubmed">22488075</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollack A., Kontorovich A. R., Fuster V., Dec G. W., Viral myocarditis&#x2014;Diagnosis, treatment options, and current controversies. Nat. Rev. Cardiol. 12, 670&#x2013;680 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26194549</ArticleId></ArticleIdList></Reference><Reference><Citation>Towbin J. A., Lowe A. M., Colan S. D., Sleeper L. A., Orav E. J., Clunie S., Messere J., Cox G. F., Lurie P. R., Hsu D., Canter C., Wilkinson J. D., Lipshultz S. E., Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 296, 1867&#x2013;1876 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17047217</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber S., Ramsingh A. I., Coxsackievirus-induced pancreatitis. Viral Immunol. 17, 358&#x2013;369 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15357902</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q. Y., Wang Y. P., Bian L. L., Xu M., Liang Z. L., EV-A71 vaccine licensure: A first step for multivalent enterovirus vaccine to control HFMD and other severe diseases. Emerg. Microbes Infect. 5, e75 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5141264</ArticleId><ArticleId IdType="pubmed">27436364</ArticleId></ArticleIdList></Reference><Reference><Citation>Hy&#xf6;ty H., Leon F., Knip M., Developing a vaccine for type 1 diabetes by targeting coxsackievirus B. Expert Rev. Vaccines 17, 1071&#x2013;1083 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30449209</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugo D., Krogstad P., Enteroviruses in the early 21st century: New manifestations and challenges. Curr. Opin. Pediatr. 28, 107&#x2013;113 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4750492</ArticleId><ArticleId IdType="pubmed">26709690</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennert R., Crijns H. J., Heymans S., Acute viral myocarditis. Eur. Heart J. 29, 2073&#x2013;2082 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2519249</ArticleId><ArticleId IdType="pubmed">18617482</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S. J., Morgan N. G., Enteroviral infections in the pathogenesis of type 1 diabetes: New insights for therapeutic intervention. Curr. Opin. Pharmacol. 43, 11&#x2013;19 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6294842</ArticleId><ArticleId IdType="pubmed">30064099</ArticleId></ArticleIdList></Reference><Reference><Citation>Principi N., Berioli M. G., Bianchini S., Esposito S., Type 1 diabetes and viral infections: What is the relationship? J. Clin. Virol. 96, 26&#x2013;31 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28934695</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunne J. L., Richardson S. J., Atkinson M. A., Craig M. E., Dahl-J&#xf8;rgensen K., Flodstr&#xf6;m-Tullberg M., Hy&#xf6;ty H., Insel R. A., Lernmark &#xc5;., Lloyd R. E., Morgan N. G., Pugliese A., Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes. Diabetologia 62, 744&#x2013;753 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450860</ArticleId><ArticleId IdType="pubmed">30675626</ArticleId></ArticleIdList></Reference><Reference><Citation>Laitinen O. H., Honkanen H., Pakkanen O., Oikarinen S., Hankaniemi M. M., Huhtala H., Ruokoranta T., Lecouturier V., Andr&#xe9; P., Harju R., Virtanen S. M., Lehtonen J., Almond J. W., Simell T., Simell O., Ilonen J., Veijola R., Knip M., Hy&#xf6;ty H., Coxsackievirus B1 is associated with induction of &#x3b2;-Cell autoimmunity that portends type 1 diabetes. Diabetes 63, 446&#x2013;455 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">23974921</ArticleId></ArticleIdList></Reference><Reference><Citation>Hankaniemi M. M., Laitinen O. H., Stone V. M., Sioofy-Khojine A., M&#xe4;&#xe4;tt&#xe4; J. A. E., Larsson P. G., Marjom&#xe4;ki V., Hy&#xf6;ty H., Flodstr&#xf6;m-Tullberg M., Hyt&#xf6;nen V. P., Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model. Vaccine 35, 3718&#x2013;3725 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28579231</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunziker I. P., Harkins S., Feuer R., Cornell C. T., Whitton J. L., Generation and analysis of an RNA vaccine that protects against coxsackievirus B3 challenge. Virology 330, 196&#x2013;208 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15527846</ArticleId></ArticleIdList></Reference><Reference><Citation>Koho T., Koivunen M. R. L., Oikarinen S., Kummola L., M&#xe4;kinen S., M&#xe4;h&#xf6;nen A. J., Sioofy-Khojine A., Marjom&#xe4;ki V., Kazmertsuk A., Junttila I., Kulomaa M. S., Hy&#xf6;ty H., Hyt&#xf6;nen V. P., Laitinen O. H., Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice. Antiviral Res. 104, 93&#x2013;101 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24485896</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson P. G., Lakshmikanth T., Laitinen O. H., Utorova R., Jacobson S., Oikarinen M., Domsgen E., Koivunen M. R. L., Chaux P., Devard N., Lecouturier V., Almond J., Knip M., Hy&#xf6;ty H., Flodstr&#xf6;m-Tullberg M., A preclinical study on the efficacy and safety of a new vaccine against Coxsackievirus B1 reveals no risk for accelerated diabetes development in mouse models. Diabetologia 58, 346&#x2013;354 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25370797</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone V. M., Hankaniemi M. M., Svedin E., Sioofy-Khojine A., Oikarinen S., Hy&#xf6;ty H., Laitinen O. H., Hyt&#xf6;nen V. P., Flodstr&#xf6;m-Tullberg M., A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes. Diabetologia 61, 476&#x2013;481 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448957</ArticleId><ArticleId IdType="pubmed">29151123</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Parham N. J., Zhang F., Aasa-Chapman M., Gould E. A., Zhang H., Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis. Vaccine 30, 2301&#x2013;2308 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22306858</ArticleId></ArticleIdList></Reference><Reference><Citation>Saarinen N. V. V., Laiho J. E., Richardson S. J., Zeissler M., Stone V. M., Marjom&#xe4;ki V., Kantoluoto T., Horwitz M. S., Sioofy-Khojine A., Honkimaa A., Hankaniemi M. M., Flodstr&#xf6;m-Tullberg M., Hy&#xf6;ty H., Hyt&#xf6;nen V. P., Laitinen O. H., A novel rat CVB1-VP1 monoclonal antibody 3A6 detects a broad range of enteroviruses. Sci. Rep. 8, 33 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5758616</ArticleId><ArticleId IdType="pubmed">29311608</ArticleId></ArticleIdList></Reference><Reference><Citation>Buschard K., What causes type 1 diabetes? Lessons from animal models. APMIS Suppl. 119, 1&#x2013;19 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21615797</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y. J., Lee J. Y., Jang Y. H., Seo S.-U., Chang J., Seong B. L., Non-specific effect of vaccines: Immediate protection against respiratory syncytial virus infection by a live attenuated influenza vaccine. Front. Microbiol. 9, 83 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5797773</ArticleId><ArticleId IdType="pubmed">29445364</ArticleId></ArticleIdList></Reference><Reference><Citation>Flodstr&#xf6;m M., Horwitz M. S., Maday A., Balakrishna D., Rodriguez E., Sarvetnick N., A critical role for inducible nitric oxide synthase in host survival following coxsackievirus B4 infection. Virology 281, 205&#x2013;215 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11277693</ArticleId></ArticleIdList></Reference><Reference><Citation>Flodstr&#xf6;m-Tullberg M., Hultcrantz M., Stotland A., Maday A., Tsai D., Fine C., Williams B., Silverman R., Sarvetnick N., RNase L and double-stranded RNA-dependent protein kinase exert complementary roles in islet cell defense during coxsackievirus infection. J. Immunol. 174, 1171&#x2013;1177 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15661870</ArticleId></ArticleIdList></Reference><Reference><Citation>Flodstr&#xf6;m M., Maday A., Balakrishna D., Cleary M. M., Yoshimura A., Sarvetnick N., Target cell defense prevents the development of diabetes after viral infection. Nat. Immunol. 3, 373&#x2013;382 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11919579</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhesus Macaque Genome Sequencing and Analysis Consortium, Gibbs R. A., Rogers J., Katze M. G., Bumgarner R., Weinstock G. M., Mardis E. R., Remington K. A., Strausberg R. L., Venter J. C., Wilson R. K., Batzer M. A., Bustamante C. D., Eichler E. E., Hahn M. W., Hardison R. C., Makova K. D., Miller W., Milosavljevic A., Palermo R. E., Siepel A., Sikela J. M., Attaway T., Bell S., Bernard K. E., Buhay C. J., Chandrabose M. N., Dao M., Davis C., Delehaunty K. D., Ding Y., Dinh H. H., Dugan-Rocha S., Fulton L. A., Gabisi R. A., Garner T. T., Godfrey J., Hawes A. C., Hernandez J., Hines S., Holder M., Hume J., Jhangiani S. N., Joshi V., Khan Z. M., Kirkness E. F., Cree A., Fowler R. G., Lee S., Lewis L. R., Li Z., Liu Y.-s., Moore S. M., Muzny D., Nazareth L. V., Ngo D. N., Okwuonu G. O., Pai G., Parker D., Paul H. A., Pfannkoch C., Pohl C. S., Rogers Y. H., Ruiz S. J., Sabo A., Santibanez J., Schneider B. W., Smith S. M., Sodergren E., Svatek A. F., Utterback T. R., Vattathil S., Warren W., White C. S., Chinwalla A. T., Feng Y., Halpern A. L., Hillier L. W., Huang X., Minx P., Nelson J. O., Pepin K. H., Qin X., Sutton G. G., Venter E., Walenz B. P., Wallis J. W., Worley K. C., Yang S. P., Jones S. M., Marra M. A., Rocchi M., Schein J. E., Baertsch R., Clarke L., Cs&#xfc;r&#xf6;s M., Glasscock J., Harris R. A., Havlak P., Jackson A. R., Jiang H., Liu Y., Messina D. N., Shen Y., Song H. X., Wylie T., Zhang L., Birney E., Han K., Konkel M. K., Lee J., Smit A. F., Ullmer B., Wang H., Xing J., Burhans R., Cheng Z., Karro J. E., Ma J., Raney B., She X., Cox M. J., Demuth J. P., Dumas L. J., Han S. G., Hopkins J., Karimpour-Fard A., Kim Y. H., Pollack J. R., Vinar T., Addo-Quaye C., Degenhardt J., Denby A., Hubisz M. J., Indap A., Kosiol C., Lahn B. T., Lawson H. A., Marklein A., Nielsen R., Vallender E. J., Clark A. G., Ferguson B., Hernandez R. D., Hirani K., Kehrer-Sawatzki H., Kolb J., Patil S., Pu L. L., Ren Y., Smith D. G., Wheeler D. A., Schenck I., Ball E. V., Chen R., Cooper D. N., Giardine B., Hsu F., Kent W. J., Lesk A., Nelson D. L., O'brien W. E., Pr&#xfc;fer K., Stenson P. D., Wallace J. C., Ke H., Liu X. M., Wang P., Xiang A. P., Yang F., Barber G. P., Haussler D., Karolchik D., Kern A. D., Kuhn R. M., Smith K. E., Zwieg A. S., Evolutionary and biomedical insights from the rhesus macaque genome. Science 316, 222&#x2013;234 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17431167</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Qin S., Ding Y., Wei L., Zhang J., Li H., Bu H., Lu Y., Cheng J., Reference values of clinical chemistry and hematology parameters in rhesus monkeys (Macaca mulatta). Xenotransplantation 16, 496&#x2013;501 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">20042049</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson E. A., Ols S., Miura K., Rausch K., Narum D. L., Sp&#xe5;ngberg M., Juraska M., Wille-Reece U., Weiner A., Howard R. F., Long C. A., Duffy P. E., Johnston L., O&#x2019;Neil C. P., Lor&#xe9; K., TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25. JCI Insight 3, 1206982 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6012510</ArticleId><ArticleId IdType="pubmed">29769448</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi X. M., Xiong S. D., Intein-mediated backbone cyclization of VP1 protein enhanced protection of CVB3-induced viral myocarditis. Sci. Rep. 7, 41485 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5288654</ArticleId><ArticleId IdType="pubmed">28148910</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson P. G., Lakshmikanth T., Svedin E., King C., Flodstr&#xf6;m-Tullberg M., Previous maternal infection protects offspring from enterovirus infection and prevents experimental diabetes development in mice. Diabetologia 56, 867&#x2013;874 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23344730</ArticleId></ArticleIdList></Reference><Reference><Citation>See D. M., Tilles J. G., Efficacy of a polyvalent inactivated-virus vaccine in protecting mice from infection with clinical strains of group B coxsackieviruses. Scand. J. Infect. Dis. 26, 739&#x2013;747 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7747099</ArticleId></ArticleIdList></Reference><Reference><Citation>Nandi D., Rossano J. W., Epidemiology and cost of heart failure in children. Cardiol. Young 25, 1460&#x2013;1468 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4763311</ArticleId><ArticleId IdType="pubmed">26675591</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff J. F., Woodruff J. J., Involvement of T lymphocytes in the pathogenesis of coxsackie virus B3 heart disease. J. Immunol. 113, 1726&#x2013;1734 (1974).</Citation><ArticleIdList><ArticleId IdType="pubmed">4610045</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group for the TRIGR Study Group, Knip M., &#xc5;kerblom H. K., Al Taji E., Becker D., Bruining J., Castano L., Danne T., de Beaufort C., Dosch H. M., Dupre J., Fraser W. D., Howard N., Ilonen J., Konrad D., Kordonouri O., Krischer J. P., Lawson M. L., Ludvigsson J., Madacsy L., Mahon J. L., Ormisson A., Palmer J. P., Pozzilli P., Savilahti E., Serrano-Rios M., Songini M., Taback S., Vaarala O., White N. H., Virtanen S. M., Wasikowa R., Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes: The TRIGR randomized clinical trial. JAMA 319, 38&#x2013;48 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833549</ArticleId><ArticleId IdType="pubmed">29297078</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Z. C., Wang J. W., Enterovirus D68 and human respiratory infections. Semin. Respir. Crit. Care Med. 37, 578&#x2013;585 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7171721</ArticleId><ArticleId IdType="pubmed">27486738</ArticleId></ArticleIdList></Reference><Reference><Citation>Suresh S., Forgie S., Robinson J., Non-polio enterovirusdetection with acute flaccid paralysis: A systematic review. J. Med. Virol. 90, 3&#x2013;7 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">28857219</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S., Nguyen M. T., Currier M. G., Jenkins J. B., Strobert E. A., Kajon A. E., Madan-Lala R., Bochkov Y. A., Gern J. E., Roy K., Lu X., Erdman D. D., Spearman P., Moore M. L., A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques. Nat. Commun. 7, 12838 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5036149</ArticleId><ArticleId IdType="pubmed">27653379</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;m&#xe4;l&#xe4;inen S., Nurminen N., Ahlfors H., Oikarinen S., Sioofy-Khojine A. B., Frisk G., Oberste M. S., Lahesmaa R., Pesu M., Hy&#xf6;ty H., Coxsackievirus B1 reveals strain specific differences in plasmacytoid dendritic cell mediated immunogenicity. J. Med. Virol. 86, 1412&#x2013;1420 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24616040</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner J. E., Kavanagh K., Ward G. M., Auerbach B. J., Harwood H. J. Jr., Kaplan J. R., Old world nonhuman primate models of type 2 diabetes mellitus. ILAR J. 47, 259&#x2013;271 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16804200</ArticleId></ArticleIdList></Reference><Reference><Citation>Sioofy-Khojine A. B., Lehtonen J., Nurminen N., Laitinen O. H., Oikarinen S., Huhtala H., Pakkanen O., Ruokoranta T., Hankaniemi M. M., Toppari J., V&#xe4;h&#xe4;-M&#xe4;kil&#xe4; M., Ilonen J., Veijola R., Knip M., Hy&#xf6;ty H., Coxsackievirus B1 infections are associated with the initiation of insulin-driven autoimmunity that progresses to type 1 diabetes. Diabetologia 61, 1193&#x2013;1202 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29404673</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>